| CARLSBAD,
Calif.--(BUSINESS WIRE)--Dec. 8, 2004--SD Pharmaceuticals
Inc. (SDP) today announced that it has completed filing
six U.S. and two international patents covering unique
nano-emulsion formulations for a variety of intravenous
drugs to treat cancer and infectious disease. The formulations
are specifically designed to improve the safety profile
and remove black box warnings on four currently marketed
therapeutically important drugs which suffer from formulation
related adverse effects. The Company is actively seeking
marketing partners to complete the clinical development
of these products and market them.
"Our business strategy is to improve the safety
of currently marketed intravenous drugs that have
formulation related black box warnings and reformulate
them to eliminate these toxic side effects. This permits
us to resurrect the proprietary status of the drug
and generate a safer product via a 505b2 product registration.
We are pleased to have established an extensive patent
portfolio on the reformulation of three currently
marketed cancer drugs and an antibiotic, all of which
are 505b2 products with global markets in excess of
$200 million each," stated SDP Chairman and CEO,
Dr. Paul J. Marangos.
SDP was founded by Drs. Paul
J. Marangos and Andrew X. Chen to remedy specific
formulation related toxicities of intravenous drugs
carrying black box warnings. The SDP scientific founder,
Dr. Andrew X. Chen, has devised novel nano-emulsion
formulations of several widely used acute care intravenous
drugs that eliminate the severe toxicities such as
anaphylactic shock, vein irritation and phlebitis
associated with the currently marketed formulations.
More information on the Company's multiple near term
product opportunities is available at www.sdpharma.com.
Contacts
SD Pharmaceuticals Inc.
Paul J. Marangos, 619-787-4083
pjm@sdpharma.com
|
